A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) (NCT05094336)
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (75 Sites)
Showing the first 25 of 75 sites.
- City of Hope National Medical Center — Duarte, California
- California Research Institute — Glendale, California
- Fomat Medical Research — Oxnard, California
- University of California at SF — San Francisco, California
- D and H Cancer Research Center — Margate, Florida
- Boca Raton Clinical Research Medical Center Inc — Tamarac, Florida
- Goshen Health Systems — Goshen, Indiana
- Indiana University — Indianapolis, Indiana
- Community Health Network MD Anderson Cancer Center - North — Indianapolis, Indiana
- University of Maryland Medical Center — Baltimore, Maryland
- American Oncology Partners, PA — Bethesda, Maryland
- Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion) — Detroit, Michigan
- Washington University — St Louis, Missouri
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health Monter Cancer Center — Lake Success, New York
- New York University Grossman School of Medicine and New York University Langone Hospitals — New York, New York
- Duke University — Durham, North Carolina
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- Thomas Jefferson University — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Sanford Oncology Clinic and Pharmacy — Sioux Falls, South Dakota
- Sarah Cannon Research Institute — Dallas, Texas
- Center for Oncology and Blood Disorders — Houston, Texas
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Advanced MTAP-null Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.